Oramed Pharmaceuticals Inc (ORMP)
Healthcare
Biotechnology
4.10 $
-1.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Oramed Pharmaceuticals Inc (ORMP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.5% of the shares are freely tradable; institutional investors hold 37.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
37.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
17.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
77.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
1.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
41Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BML Capital Management LLC | 7.74 | 3,167,231 | +0.0 | 03/31/2026 |
| Aquamarine Financial (Cayman) Ltd | 5.16 | 2,112,312 | +7.1 | 03/31/2026 |
| Mercer Global Advisors Inc. | 4.67 | 1,910,540 | +0.0 | 03/31/2026 |
| Sb Capital Management Inc | 4.64 | 1,900,000 | +0.0 | 12/31/2025 |
| Gem Investment Advisors, LLC | 4.01 | 1,640,069 | -17.9 | 03/31/2026 |
| Murchinson Ltd. | 3.21 | 1,315,294 | -1.9 | 03/31/2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.47 | 600,716 | -1.9 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 0.63 | 259,611 | +0.2 | 03/31/2026 |
| Rathbone Brothers PLC | 0.57 | 233,018 | +0.0 | 03/31/2026 |
| Dimensional Fund Advisors, Inc. | 0.39 | 158,209 | +5.1 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.